TIDMAGL

RNS Number : 0792B

Angle PLC

29 September 2022

 
 For Immediate Release   29 September 2022 
 

ANGLE plc

("ANGLE" or "the Company")

Interim Results for the six months ended 30 June 2022

FDA CLEARANCE A MAJOR BREAKTHROUGH FOR PARSORTIX LIQUID BIOPSY

Prostate cancer partnership signed with Solaris Health

Positive ovarian cancer headline results announced today

ANGLE plc (AIM: AGL OTCQX: ANPCY), a world leading liquid biopsy company, today announces its unaudited interim financial results for the six months ended 30 June 2022.

Operational Highlights

-- FDA De Novo clearance received for the Parsortix(R) system for its intended use with metastatic breast cancer (MBC) patients

- first ever FDA product clearance to harvest cancer cells from a patient blood sample for subsequent user-validated analysis

- first mover advantage for intact cancer cell analysis in the global liquid biopsy market

- with FDA clearance and CE Mark in place, commercial roll-out underway with global distributor network being established

   --    Global pharma services business momentum encouraging 

- additional $1.2 million contract from first large-scale pharma services customer in new clinical trial

- increased pharma industry engagement post FDA clearance

- excellent progress with first bespoke assay customer with DNA damage repair assay successfully developed

   --    Analysis of samples from ovarian cancer clinical verification study completed 

- excellent headline results with ROC-AUC 95.4%, as separately announced today

- results demonstrate clinical validity employing molecular analysis of cancer cells captured using the Parsortix system in a difficult to diagnose real world setting

   --    Partnership established with Solaris Health, a major United States urology group 

- collaboration to evaluate the Parsortix system in prostate cancer clinical studies, addressing major unmet medical needs

- Solaris Health offers route to market through its extensive patient base

Financial Highlights

   --    Revenue for the half-year GBP0.4 million (H1 2021: GBP0.3 million) 
   --    Loss for the half-year GBP9.2 million (H1 2021: GBP7.7 million) reflecting planned investment 

-- Cash and cash equivalents at 30 June 2022 of GBP20.5 million (31 December 2021: GBP31.8 million)

-- Post period end, a further GBP20.1 million (GBP18.9 million net of expenses) was raised in a placing which was supported by new and existing institutional investors in both the UK and United States as well as senior management

Outlook

-- Pharma services business momentum - discussions in progress with more than twenty biopharma companies offering a pipeline of opportunities for new contracts as we move through the end of this year and into 2023. Almost all potential customers are interested in bespoke assay development

-- Global sales and distribution network being established with first contracts in negotiation and initial seeding of instruments anticipated

-- Accreditation of clinical laboratories in final stages offering ability to offer validated tests for both pharma services and patient management in coming months

-- New product roll-out to accelerate with a pipeline of sample-to-answer imaging and molecular solutions being finalised for offer to customers

-- Numerous discussions in progress with potential partners including medtech companies, downstream assay providers and clinical laboratories regarding selected Parsortix based assays

-- Continued investment in clinical studies to provide clinical evidence to support long term growth

Garth Selvey, Non-Executive Chairman of ANGLE plc, commented:

"I am delighted that during the period the FDA granted a De Novo Class II classification for the Parsortix system for use in harvesting cancer cells from metastatic breast cancer patient blood for subsequent user-validated analysis. Clearance substantially differentiates ANGLE from the competition and is expected to significantly accelerate commercial adoption of the system in both research and clinical settings.

ANGLE's global pharma services business is gaining traction, with a notable increase in potential customer engagement in the weeks post-FDA clearance and subsequently. We are pleased to see repeat business already coming through from an early major customer and the successful development of our first bespoke assay for another as we start to build our service offering 'menu'.

Demonstration of clinical utility is a key strategic goal for the Company. The positive headline results for the ovarian cancer pelvic mass triage test announced today provide a real world example of the value of molecular analysis of the Parsortix harvest of circulating tumour cells and support the Company's view that this is the "best sample" for analysis for a liquid biopsy.

Shortly after the period end, ANGLE successfully completed a fundraising of GBP20.1 million (GBP18.9 million net of expenses). Recognising the current adverse market conditions and wider macroeconomic environment, ANGLE continues to keep a tight focus on building revenues, controlling costs and maximising the cash runway within available funds whilst ensuring key commercial milestones are delivered."

Details of webcast

A virtual meeting and webcast for analysts will be held at 11:00 am BST today. If you wish to attend, please register in advance and log on to the webcast approximately 5 minutes before 11.00 am. Details of how to attend can be accessed via https://angleplc.com/investor-relations/corporate-presentations/ .

For further information:

 
 ANGLE plc                                        +44 (0) 1483 343434 
 Andrew Newland, Chief Executive 
  Ian Griffiths, Finance Director 
  Andrew Holder, Head of Investor Relations 
 Berenberg (NOMAD and Joint Broker) 
  Toby Flaux, Ciaran Walsh, Milo Bonser           +44 (0) 20 3207 7800 
 
   Jefferies (Joint Broker) 
   Max Jones, Thomas Bective                        +44 (0) 20 7029 8000 
 
   FTI Consulting 
   Simon Conway, Ciara Martin                       +44 (0) 203 727 1000 
   Matthew Ventimiglia (US)                         +1 (212) 850 5624 
 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the EU Market Abuse Regulation (596/2014) . Upon the publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

For Frequently Used Terms, please see the Company's website on https://angleplc.com/investor-relations/glossary/

These Interim Results may contain forward-looking statements. These statements reflect the Board's current view, are subject to a number of material risks and uncertainties and could change in the future. Factors that could cause or contribute to such changes include, but are not limited to, the impact of the COVID-19 pandemic, the general economic climate and market conditions, as well as specific factors including the success of the Group's research and development activities, commercialisation strategies, the uncertainties related to clinical study outcomes and regulatory clearance, obtaining reimbursement and payor coverage, acceptance into national guidelines and the acceptance of the Group's products by customers.

CHAIRMAN'S STATEMENT

The ground-breaking first ever FDA product clearance in metastatic breast cancer heralds a new era for personalised cancer care and provides the platform for ANGLE to work with our collaborators and customers to support further FDA submissions and the establishment of numerous specific clinical uses across different cancer types. By making the Parsortix system widely available, we intend to support the entire industry in its adoption of liquid biopsy solutions for repeat non-invasive diagnostics for personalised cancer care. Large-scale medtech and pharma companies now have an FDA cleared platform on which to develop new medical solutions and ANGLE aims to capitalise on this opportunity as it begins the commercial roll-out of the system. Progress is being made, both with complex molecular analysis solutions, such as the ovarian results announced today, and with low-cost downstream analysis techniques such as Pap stain showcased earlier this month at the American Society for Clinical Pathology (ASCP) meeting in Chicago, Illinois, USA. We expect both of these approaches to positively impact nearer term adoption of the system.

Overview of Financial Results

Revenue of GBP0.4 million in the period (six months ended 30 June 2021: GBP0.3 million) was driven by research use sales of the Parsortix system along with an initial contribution from the pharma services business, including both clinical trial services and bespoke assay development. ANGLE expects the positive impact of FDA clearance on revenues to begin in the second half and gather momentum thereafter. The Company has continued its investment in studies to develop and validate the clinical application and commercial use of the Parsortix system and further build out the clinical laboratories and pharma services business capacity, resulting in operating costs of GBP10.6 million (six months ended 30 June 2021: GBP8.9 million) and a loss for the period of GBP9.2 million (six months ended 30 June 2021: loss GBP7.7 million).

Cash and cash equivalents was GBP20.5 million at 30 June 2022 (31 December 2021: GBP31.8 million) with R&D Tax Credits due at 30 June 2022 of GBP5.9 million (31 December 2021: GBP4.5 million). Post period end, the cash position was strengthened with a successful placing of new shares with support from new and existing UK and United States institutional investors as well as senior management, which raised net proceeds of GBP18.9 million.

FDA Clearance

On 25 May 2022, FDA granted a De Novo Class II classification for the Parsortix system for use in harvesting cancer cells from metastatic breast cancer (MBC) patient blood for subsequent analysis. This means that an entirely new medical device classification has been granted by FDA for the Parsortix system. De Novo clearance is extremely challenging and costly and consequently is rare and this is the first such medical device classification for a new instrument in oncology for many years.

The commercial roll-out is now underway, with launch events held at the American Society for Clinical Chemistry (AACC) meeting in Chicago and the Next Generation Dx Summit in Washington D.C. Most recently, ANGLE presented a new poster at the 100(th) American Society for Clinical Pathology (ASCP) in Chicago, demonstrating that patient sample CTC analysis can be performed by combining the use of the Parsortix system with standard cytology Pap staining. This offers the potential to place the system in standardised, low-cost laboratory workflows, accelerating the adoption by pathology laboratories.

ANGLE is encouraged by the interest and discussions are beginning with several leading cancer centres in the United States as well as a UK Government agency. ANGLE is also looking to exploit the FDA clearance and European CE Mark through distributor arrangements in key territories outside the United States and contractual negotiations are in progress.

Clinical laboratories

ANGLE has established clinical laboratories in the UK and United States that have the capability of processing patient samples and offering validated clinical tests. The laboratories, in Guildford, UK and Plymouth Meeting, Pennsylvania, United States are being used as accelerators and demonstrators in support of product sales of Parsortix instruments and cassettes and to provide services to pharmaceutical and biotech customers running clinical trials.

Processing of patient samples for clinical purposes requires the laboratories to be accredited under the appropriate local regulatory regimes. In March 2022, the Centers for Medicare and Medicaid Services (CMS) issued a Certificate of Registration, under the CLIA process, to the Company's United States clinical laboratory. This is a key step towards achieving CLIA accreditation of the laboratory. Following a satisfactory CMS audit, including an inspection of the facilities and documentation on the validation of assays to be performed together with associated quality control procedures, a Certificate of Compliance will be issued. This will complete the accreditation process that permits the laboratory to process samples for patient management from the majority of the United States, with a small number of States requiring additional procedures which will be progressed separately.

ANGLE has made good progress in the in-house development of a pipeline of new products in addition to the Pap stain assay, including a sample-to-answer Portrait(+) imaging solution for the identification of epithelial and mesenchymal CTCs as well as CTCs in the process of epithelial mesenchymal transition (EMT). A Portrait(+) PD-L1 assay is also nearing completion, enabling the ability to identify this key target protein for immunotherapy on CTCs harvested using the Parsortix system. These products can be offered to both pharma services customers for use in clinical trials or the development of companion diagnostics or to clinical customers for the development of laboratory developed tests.

Global pharma services business

Despite lengthy initial sales processes (detailing the analysis capability, evidencing the laboratory quality systems, and agreeing the sampling handling and reporting requirements), ANGLE has already successfully secured pharma services contracts with four pharma and biotech companies to date and discussions are ongoing with more than twenty companies providing a pipeline of opportunities that the Company expects to convert into contracts in the future.

Importantly, on 22 June this year, ANGLE announced it had secured an additional contract with its first large-scale pharma services customer. The customer, a pharma company with numerous cancer drugs under development and revenues exceeding US$1 billion per annum, again selected ANGLE's Parsortix system to undertake longitudinal monitoring (i.e. before, during and after drug intervention) of patients with certain unresectable solid tumours in a new Phase Ib dose-escalation study using its investigational drug in combination with immuno-oncology agents. Once the recommended dose has been determined, the study will progress to an expansion stage.

The additional contract is expected to be worth up to US$1.2 million over a multi-year period. The new work relates to the successful progression of one of the smaller Phase I studies in the original contract announced in April 2021. This dose-escalation study, with expansion stage, is now in progress and the customer expects to provide samples from each patient for analysis by ANGLE at as many as seven separate timepoints.

The additional contract from its first large-scale pharma customer, as well as ongoing discussions with multiple potential new customers, validates ANGLE's belief that longitudinal monitoring of CTCs is a highly attractive proposition for the pharma industry looking for new insights in cancer drug trials.

Bespoke assay development as a first phase in pharma services is expected to significantly increase the attractiveness of the Parsortix CTC analysis offering, as pharma clients can look at proteins on CTCs which directly align with the mechanism of action of their drug under investigation. ANGLE has made excellent progress in this regard and has completed the development work for its first assay development customer. The assay successfully identifies on CTCs two target proteins implicated in DNA damage repair, an area of significant interest to drug companies developing PARP inhibitors for a range of solid tumours.

This assay, alongside any further assays developed by ANGLE, can now be added to a menu of pre-developed tests that can be offered to other customers. Pharma companies are particularly interested in investigating protein markers on actual cancer cells. These cannot be investigated using the alternative liquid biopsy approach ctDNA (fragments of dead cancer cells) since protein cannot be measured on ctDNA. Tissue biopsies provide cancer cells but cannot be used for longitudinal monitoring since only a single time point is usually possible with tissue biopsy. Consequently, pharma companies are unable to access this analysis without analysing CTCs.

Clinical applications

COVID-19 related supply chain difficulties impacting the ovarian cancer study were resolved during the period and analysis of samples completed. Headline results for the study were separately announced today. The performance of the Parsortix Landscape(+) Ovarian assay in this study was in-line with the high level of accuracy demonstrated in an earlier 200 patient multicentre clinical study reported in 2018 (ROC-AUC 95.1%) and achieved the Company's objective of best in class results with both sensitivity and specificity of 90% or greater.

ANGLE believes the clinical data from this study provides a clear demonstration of the value of the Parsortix harvest as the "best sample" for analysis for liquid biopsy. This is possible because the Parsortix system recovers intact living cancer cells in the patient blood, which contrasts with other tests based on free-floating proteins that can be upregulated for reasons other than cancer, or fragments of dead cancer cells, where only a partial DNA picture is available.

The test utilises comprehensive gene expression information derived from blood samples shipped overnight to a central laboratory, uses a lysis buffer that does not require the separate extraction of RNA from the population of cells captured by the Parsortix system, and does not directly rely on the use of serum biomarkers. The clinical results therefore demonstrate, in a real world setting, the ability to undertake complex molecular analysis of the Parsortix harvest and confirms its suitability for use in both hospital laboratories and central laboratories requiring sample shipping. ANGLE believes that these key findings provide evidence of the potential for widespread use of the Parsortix system for molecular analysis in numerous different cancer applications adding greatly to the value of the FDA cleared Parsortix system.

ANGLE is finalising detailed plans for commercialisation of Parsortix Landscape(+) molecular assays including but not limited to ovarian cancer.

During the period, ANGLE also announced it had signed a master clinical study agreement with Solaris Health Holdings, LLC (Solaris) and joinder agreements with MidLantic Urology LLC, to collaborate and conduct clinical studies in prostate cancer and as a potential route to market in the United States.

MidLantic Urology, an affiliate of Solaris, is one of the largest providers of specialist urology services in the United States with more than 70 physicians operating from 47 dedicated urology centres across the state of Pennsylvania. The Solaris Health network encompasses more than 500 clinical urology providers across 179 locations and nine States with more than 729,000 unique patients annually.

Together with MidLantic Urology, ANGLE will initiate clinical studies aimed at investigating the use of the Parsortix(R) system for the detection of prostate cancer and prediction of its severity in patients who present with an elevated prostate specific antigen (PSA) level and/or abnormal digital rectal exam.

This study will initially enrol 100 men scheduled to undergo a prostate tissue biopsy at a minimum of three study sites over an anticipated period of up to nine months. Blood samples collected by MidLantic Urology will be shipped to ANGLE's United States clinical laboratory for processing by the Parsortix system to harvest and analyse CTCs and associated immune cells. The Parsortix harvests will be evaluated by both imaging and molecular analysis to assess the potential to predict the presence of clinically significant prostate cancer prior to tissue biopsy and to assess potential correlation with established disease severity scores (e.g. the Gleason score) in those patients found to have prostate cancer. Headline results are anticipated in late 2023.

Solaris could be ANGLE's first route to market for this test, offering the established test to their extensive patient base and opening up a significant market opportunity for ANGLE. Successful results could also allow the design of a larger validation study to support an eventual submission to FDA and other regulatory bodies for this application.

Outlook

The first ever FDA product clearance for a system to harvest cancer cells for subsequent analysis is a major breakthrough for ANGLE and is expected to positively impact all areas of our business. There has been a notable increase in clinical and research laboratory engagement since clearance, and we expect this to continue, leading to first clinical product placements and new pharma services contracts as commercial discussions mature. The recent proof of concept using standardised low-cost cytology staining techniques for CTC identification and analysis is particularly encouraging and should assist clinical adoption by third party laboratories.

ANGLE continues to explore partnerships with major medical device and diagnostics companies and is encouraged by the increased engagement and more detailed discussions post FDA clearance. In addition, several downstream assay developers and technology providers are looking to combine CTC analysis using the Parsortix system to enhance their own offering.

Following the excellent results announced today utilising molecular analysis for ovarian cancer in a real world setting for a difficult to diagnose cancer, ANGLE is now finalising detailed plans for commercialisation of Parsortix Landscape(+) molecular assays including but not limited to ovarian cancer. Molecular analysis of Parsortix harvests opens up a multitude of applications for ANGLE's customers and has widespread potential application.

Recognising the current adverse market conditions and wider macroeconomic environment, ANGLE will continue to keep a tight focus on building revenues, controlling costs and maximising the cash runway within available funds whilst ensuring key commercial milestones are delivered.

ANGLE continues to believe that clinical adoption of liquid biopsy solutions for cancer diagnosis is building in all major markets and that, with new pricing legislation in the United States, drug developers are under increasing pressure to improve clinical trial efficiency and support market acceptance for novel cancer treatments, which require companion diagnostics (CDx) for which Parsortix is ideally suited. With FDA clearance for the Parsortix system now in place, ANGLE is well positioned to capitalise on these opportunities.

Garth Selvey

Chairman

28 September 2022

ANGLE plc

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

FOR THE SIX MONTHSED 30 JUNE 2022

 
                                                                 Six months 
                                        Six months ended              ended       Year ended 
                                                 30 June            30 June      31 December 
                                                    2022               2021             2021 
                                             (Unaudited)        (Unaudited)        (Audited) 
                                      Note       GBP'000            GBP'000          GBP'000 
 Revenue                                             419                296            1,013 
 Cost of sales                                _____(160)   ____________(77)   _________(302) 
 Gross profit                                        259                219              711 
 Other operating income                                1                 16               41 
 Operating costs                             ___(10,626)   _________(8,897)   ______(17,987) 
 Operating profit/(loss)                        (10,366)            (8,662)         (17,235) 
 Finance income                                       32                 16               29 
 Finance costs                                _____(170)   ____________(73)   _________(157) 
 Profit/(loss) before tax                       (10,504)            (8,719)         (17,363) 
 Tax (charge)/credit                   2      _____1,283   ___________1,036   _________2,351 
 Profit/(loss) for the period                    (9,221)            (7,683)         (15,012) 
 Other comprehensive income/(loss) 
  Items that may be subsequently 
  reclassified to profit or loss 
 Exchange differences on translating 
  foreign operations                         ____(1,928)       _________172   _________(175) 
 Other comprehensive income/(loss)           ____(1,928)       _________172   _________(175) 
 Total comprehensive income/(loss) 
  for the period                                (11,149)            (7,511)         (15,187) 
                                              ==========      =============     ============ 
 Earnings/(loss) per share attributable to owners of the parent 
 Basic and Diluted (pence 
  per share)                           3          (3.92)             (3.57)           (6.67) 
 

All activity arose from continuing operations

ANGLE PLC

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

AS AT 30 JUNE 2022

 
                                            30 June            30 June   31 December 
                                               2022               2021          2021 
                                        (Unaudited)        (Unaudited)     (Audited) 
                                    Note    GBP'000            GBP'000       GBP'000 
 Assets 
   Non-current assets 
   Intangible assets                          3,590              3,653         3,573 
   Property, plant and equipment              3,183              2,005         2,172 
   Right-of-use assets                        5,083              2,404         2,204 
                                          ---------      -------------  ------------ 
   Total non-current assets                  11,856              8,062         7,949 
                                          ---------      -------------  ------------ 
 
   Current assets 
   Inventories                                1,734              1,076         1,748 
   Trade and other receivables                1,832              1,388         1,269 
   Taxation                                   5,883              3,195         4,510 
   Short-term deposits                            -             11,550             - 
   Cash and cash equivalents                 20,497              9,481        31,839 
                                          ---------      -------------  ------------ 
  Total current assets                       29,946             26,690        39,366 
                                          ---------      -------------  ------------ 
 
 Total assets                                41,802             34,752        47,315 
                                          =========      =============  ============ 
 Liabilities 
    Non-current liabilities 
    Lease liabilities                       (4,672)            (1,926)       (1,816) 
    Trade and other payables                  (686)            (1,645)         (257) 
                                          ---------      -------------  ------------ 
   Total non-current liabilities            (5,358)            (3,571)       (2,073) 
   Current liabilities 
   Lease liabilities                          (565)              (683)         (522) 
   Trade and other payables                 (4,004)            (3,026)       (4,390) 
                                          ---------      -------------  ------------ 
   Total current liabilities                (4,569)            (3,709)       (4,912) 
 
 Total liabilities                          (9,927)            (7,280)       (6,985) 
                                          ---------      -------------  ------------ 
 Net assets                                  31,875             27,472        40,330 
                                          =========      =============  ============ 
 Equity 
   Share capital                     4       23,529             21,586        23,514 
   Share premium                             99,467             81,731        99,406 
   Share-based payments reserve               5,057              2,058         2,727 
   Other reserve                              2,553              2,553         2,553 
   Translation reserve                      (5,888)            (3,613)       (3,960) 
   Accumulated losses                      (92,741)           (76,741)      (83,808) 
   ESOT shares                                (102)              (102)         (102) 
                                          ---------      -------------  ------------ 
 Total equity                                31,875             27,472        40,330 
                                          =========      =============  ============ 
 

ANGLE plc

CONSOLIDATED STATEMENT OF CASH FLOWS

FOR THE SIX MONTHSED 30 JUNE 2022

 
                                                  Six months     Six months            Year 
                                                       ended          ended           ended 
                                                     30 June        30 June     31 December 
                                                        2022           2021            2021 
                                                 (Unaudited)    (Unaudited)       (Audited) 
                                                     GBP'000        GBP'000         GBP'000 
 Operating activities 
    Profit/(loss) before tax from continuing 
     operations                                     (10,504)        (8,719)        (17,363) 
    Adjustments for: 
       Depreciation of property, plant 
        and equipment                                    415            313             701 
       Depreciation of right-of-use assets               467            260             532 
       (Profit)/loss on disposal of property, 
        plant and equipment                                -              -               4 
       Amortisation and impairment of 
        intangible assets                                103            114             254 
       Share-based payments                            2,618            394           1,325 
       Exchange differences                          (2,030)            171           (170) 
                                                                    _______ 
       Net finance (income)/costs                  ______138             57     ________128 
    Operating cash flows before movements 
     in working capital:                             (8,793)        (7,410)        (14,589) 
       (Increase)/decrease in inventories              (153)          (355)         (1,015) 
       (Increase)/decrease in trade and 
        other receivables                              (691)            105             204 
       Increase/(decrease) in trade and 
        other payables                            _____(445)    ______1,331    _______1,417 
    Operating cash flows                            (10,082)        (6,329)        (13,983) 
       Research and development tax credits 
        received                                           -              -               - 
       Overseas corporation tax payments           ________-    _______(11)    ________(27) 
 Net cash from/(used in) operating 
  activities                                        (10,082)        (6,340)        (14,010) 
 
   Investing activities 
    Purchase of property, plant and 
     equipment                                         (916)        (1,007)         (1,666) 
    Purchase of intangible assets                       (71)           (53)           (122) 
    Transfer (to)/from short-term deposits                 -          4,989          16,538 
    Interest received                              _______31      _______13    __________24 
 Net cash from/(used in) investing 
  activities                                           (956)          3,942          14,774 
 
   Financing activities 
    Net proceeds from issue of share 
     capital - placing                                     -            124          18,765 
    Net proceeds from issue of share 
     capital - share option exercises                     87              -             925 
    Principal elements of lease payments               (369)          (309)           (614) 
    Interest elements of lease payments           ______(62)    _______(19)    ________(85) 
 Net cash from/(used in) financing 
  activities                                           (344)          (204)          18,991 
 
   Net increase/(decrease) in cash 
   and cash equivalents                             (11,382)        (2,602)          19,755 
 Cash and cash equivalents at start 
  of period                                           31,839         12,080          12,080 
 Effect of exchange rate fluctuations             ________40   ___________3         ______4 
 Cash and cash equivalents at end 
  of period                                           20,497          9,481          31,839 
                                                 ===========    ===========         ======= 
 
 
 Cash and cash equivalents at end 
  of period                               20,497          9,481           31,839 
 Short-term deposits                  _________-   ______11,550   _____________- 
 Cash and cash equivalents and 
  short-term deposits                     20,497         21,031           31,839 
                                     ===========    ===========     ============ 
 

ANGLE plc

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

FOR THE SIX MONTHSED 30 JUNE 2022

 
                                                                     Share-based 
                                               Share         Share      payments         Other 
                                             capital       premium       reserve       reserve 
                                         (Unaudited)   (Unaudited)   (Unaudited)   (Unaudited) 
                                             GBP'000       GBP'000       GBP'000       GBP'000 
 At 1 January 2021                            21,540        81,532         1,745         2,553 
 
   For the period to 30 June 
   2021 
-------------------------------------------  -------  ------------  ------------  ------------ 
 Consolidated profit/(loss) 
 Other comprehensive income/(loss): 
 Exchange differences in translating 
  foreign operations 
 Total comprehensive income/(loss) 
 Issue of shares (net of costs)                   46           199 
 Share-based payments                                                        394 
 Released on exercise                                                       (59) 
 Released on forfeiture                                                     (22) 
-------------------------------------------  -------  ------------  ------------  ------------ 
 At 30 June 2021 (Unaudited)                  21,586        81,731         2,058         2,553 
 
   For the period to 31 December 
   2021 
-------------------------------------------  -------  ------------  ------------  ------------ 
 Consolidated profit/(loss) 
 Other comprehensive income/(loss): 
 Exchange differences in translating 
  foreign operations 
-------------------------------------------  -------  ------------  ------------  ------------ 
 Total comprehensive income/(loss) 
 Issue of shares (net of costs)                1,928        17,675 
 Share-based payments                                                        931 
 Released on exercise                                                      (236) 
 Released on forfeiture                                                     (26) 
-------------------------------------------  -------  ------------  ------------  ------------ 
 At 31 December 2021 (Audited)                23,514        99,406         2,727         2,553 
 
   For the period to 30 June 
   2022 
 Consolidated profit/(loss) 
 Other comprehensive income/(loss): 
 Exchange differences in translating 
  foreign operations 
-------------------------------------------  -------  ------------  ------------  ------------ 
 Total comprehensive income/(loss) 
 Issue of shares (net 
  of costs)                                       15            61 
 Share-based payments                                                      2,618 
 Released on exercise                                                       (21) 
 Released on forfeiture                                                    (267) 
-----------------------------  ---------------------  ------------  ------------  ------------ 
 At 30 June 2022 
  (Unaudited)                                 23,529        99,467         5,057         2,553 
=============================  =====================  ============  ============  ============ 
 
 

ANGLE plc

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

FOR THE SIX MONTHSED 30 JUNE 2022 (continued)

 
 
                                         Translation      Retained          ESOT         Total 
                                             reserve      earnings        shares        equity 
                                         (Unaudited)   (Unaudited)   (Unaudited)   (Unaudited) 
                                             GBP'000       GBP'000       GBP'000       GBP'000 
 At 1 January 2021                           (3,785)      (69,139)         (102)        34,344 
 
   For the period to 30 June 
   2021 
--------------------------------------  ------------  ------------  ------------  ------------ 
 Consolidated profit/(loss)                                (7,683)                     (7,683) 
 Other comprehensive income/(loss): 
 Exchange differences in translating 
 foreign operations                              172                                       172 
 Total comprehensive income/(loss)               172       (7,683)                     (7,511) 
 Issue of shares (net of costs)                                                            245 
 Share-based payments                                                                      394 
 Released on exercise                                           59                           - 
 Released on forfeiture                                         22                           - 
--------------------------------------  ------------  ------------  ------------  ------------ 
 At 30 June 2021 (Unaudited)                 (3,613)      (76,741)         (102)        27,472 
 
   For the period to 31 December 
   2021 
--------------------------------------  ------------  ------------  ------------  ------------ 
 Consolidated profit/(loss)                                (7,329)                     (7,329) 
 Other comprehensive income/(loss): 
 Exchange differences in translating 
 foreign operations                            (347)                                     (347) 
--------------------------------------  ------------  ------------  ------------  ------------ 
 Total comprehensive income/(loss)             (347)       (7,329)                     (7,676) 
 Issue of shares (net of costs)                                                         19,603 
 Share-based payments                                                                      931 
 Released on exercise                                          236                           - 
 Released on forfeiture                                         26                           - 
--------------------------------------  ------------  ------------  ------------  ------------ 
 At 31 December 2021 (Audited)               (3,960)      (83,808)         (102)        40,330 
 
   For the period to 30 June 
   2022 
 Consolidated profit/(loss)                                (9,221)                     (9,221) 
 Other comprehensive income/(loss): 
 Exchange differences in translating 
 foreign operations                          (1,928)                                   (1,928) 
--------------------------------------  ------------  ------------  ------------  ------------ 
 Total comprehensive income/(loss)           (1,928)       (9,221)                    (11,149) 
 Issue of shares (net of costs)                                                             76 
 Share-based payments                                                                    2,618 
 Released on exercise                                           21                           - 
 Released on forfeiture                                        267                           - 
--------------------------------------  ------------  ------------  ------------  ------------ 
 At 30 June 2022 (Unaudited)                 (5,888)      (92,741)         (102)        31,875 
======================================  ============  ============  ============  ============ 
 

ANGLE plc

NOTES TO THE CONDENSED INTERIM FINANCIAL INFORMATION

FOR THE SIX MONTHSED 30 JUNE 2022

   1       Basis of preparation and accounting policies 

This Condensed Interim Financial Information is the unaudited interim consolidated financial information (the "Condensed Interim Financial Information") of ANGLE plc, a company incorporated and domiciled in Great Britain and its subsidiaries (together referred to as the "Group") for the six month period ended 30 June 2022 (the "interim period").

The Condensed Interim Financial Information should be read in conjunction with the Financial Statements of the Group for the year ended 31 December 2021, which have been prepared in accordance with UK-adopted international accounting standards. New and revised accounting standards and interpretations that became effective in the period did not have or are not expected to have a significant impact on the Group. Where necessary, comparative information has been reclassified or expanded from the previously reported Condensed Interim Financial Information to take into account any presentational changes which were made in the Annual Report and Financial Statements to 31 December 2021 and which may be made in the Annual Report and Financial Statements to 31 December 2022.

The accounting policies used in the preparation of the Condensed Interim Financial Information for the six months ended 30 June 2022 are in accordance with UK-adopted accounting standards and are consistent with those which will be adopted in the Financial Statements for the year ended 31 December 2022. While the Condensed Interim Financial Information has been prepared in accordance with the recognition and measurement criteria of UK-adopted international accounting standards, these Financial Statements do not contain sufficient information to comply with UK-adopted international accounting standards.

This Condensed Interim Financial Information does not constitute statutory financial statements as defined in section 434 of the Companies Act 2006 and is unaudited and has not been reviewed. The comparative information for the six months ended 30 June 2021 is also unaudited. The comparative figures for the year ended 31 December 2021 have been extracted from the Group Financial Statements as filed with the Registrar of Companies. The report of the auditors on those Financial Statements was unqualified and did not contain statements under sections 498(2) or (3) of the Companies Act 2006.

The Condensed Interim Financial Information was approved by the Board and authorised for issue on 29 September 2022.

Going concern

The Financial Information has been prepared on a going concern basis which assumes that the Group will be able to continue its operations for the foreseeable future.

The Directors have considered the uncertainties, risks and potential impact on the business associated with potential negative trading scenarios, market and geopolitical uncertainty (Ukraine-Russia conflict), Brexit friction and residual COVID-19 impacts. Discretionary expenditure within the business provides flexibility to scale back operations to address adverse events if required. Mitigation measures to reduce costs could be taken if needed and other potential sources of funding exist such as grants, exclusivity and/or milestone payments for corporate partnerships being developed and equity proceeds.

The Directors have prepared and reviewed financial projections for the 12 month period from the date of approval of this Condensed Interim Financial Information with discretionary expenditure carefully controlled in line with available resources, as certain projects may be deferred until additional resources are available. Based on the level of existing cash and expected R&D tax credits, the projected income and expenditure (the quantum and timing of some of which is at the Group's discretion) and other potential sources of funding, the Directors have a reasonable expectation that the Company and Group have adequate resources to continue in business for the foreseeable future. Accordingly, the going concern basis has been used in preparing the Condensed Interim Financial Information. Note 5 provides additional information.

Critical accounting estimates and judgements

The preparation of the Condensed Interim Financial Information requires the use of estimates, assumptions and judgements that affect the reported amounts of assets and liabilities at the date of the Financial Information and the reported amounts of revenues and expenses during the reporting period. Although these estimates, assumptions and judgements are based on the Directors' best knowledge of the amounts, events or actions, and are believed to be reasonable, actual results ultimately may differ from those estimates.

The estimates, assumptions and judgements that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities relate to 1) share-based payments 2) IFRS 16 recognition of a right-of-use asset and lease liability where the property lease was effective from May 2022 but not signed until July 2022 and 3) IFRS 16 assessment of extension and/or termination options of right-of-use asset and lease liabilities.

   2      Tax 

The Group undertakes research and development activities. In the UK these activities qualify for tax relief resulting in research and development tax credits.

   2    Earnings/(loss) per share 

The basic and diluted earnings/(loss) per share is calculated by dividing the after tax loss for the period attributable to the owners of the parent of GBP9.2 million (six months to 30 June 2021: loss GBP7.7 million, year ended 31 December 2021: loss GBP15.0 million) by the weighted average number of shares in the period.

In accordance with IAS 33 Earnings per share 1) the "basic" weighted average number of Ordinary shares calculation excludes shares held by the Employee Share Ownership Trust (ESOT) as these are treated as treasury shares and 2) the "diluted" weighted average number of Ordinary shares calculation considers potentially dilutive Ordinary shares from instruments that could be converted. Share options are potentially dilutive where the exercise price is less than the average market price during the period. Due to the losses in the periods, share options are non-dilutive for the respective periods as adding them would have the effect of reducing the loss per share and therefore the diluted loss per share is equal to the basic loss per share.

The basic and diluted earnings/(loss) per share are based on 235,036,872 weighted average Ordinary GBP0.10 shares (six months to 30 June 2021: 215,440,711; year ended 31 December 2021: 225,073,380).

   4       Share capital 

The Company has one class of Ordinary shares which carry no right to fixed income and at 30 June 2022 had 235,294,716 Ordinary shares of GBP0.10 each allotted, called up and fully paid.

During the period the Company issued 151,666 new Ordinary shares with a nominal value of GBP0.10 at issue prices of GBP0.49 and GBP0.53 per share as a result of the exercise of share options by employees realising gross proceeds of GBP0.1 million. Shares were admitted to trading on AIM at various dates across the period.

   5       Post reporting date events 

As explained in the Chairman's Statement, subsequent to the reporting date the Company has completed a fundraise realising gross proceeds of GBP20.1 million (GBP18.9 million net of expenses).

Shareholder communications

This announcement is being sent to all shareholders on the register at 28 September 2022. Copies of this announcement are posted on the Company's website www.angleplc.com and are available from the Company's registered office: 10 Nugent Road, Surrey Research Park, Guildford, Surrey, GU2 7AF.

, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

IR FFFIIAIITFIF

(END) Dow Jones Newswires

September 29, 2022 02:00 ET (06:00 GMT)

Angle (LSE:AGL)
Historical Stock Chart
From Oct 2022 to Nov 2022 Click Here for more Angle Charts.
Angle (LSE:AGL)
Historical Stock Chart
From Nov 2021 to Nov 2022 Click Here for more Angle Charts.